# Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III

> **NCT02631928** · PHASE1 · COMPLETED · sponsor: **Julphar Gulf Pharmaceutical Industries** · enrollment: 73 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** human biphasic insulin
- **DRUG:** human biphasic insulin, reference

## Key facts

- **NCT ID:** NCT02631928
- **Lead sponsor:** Julphar Gulf Pharmaceutical Industries
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2016-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02631928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02631928, "Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02631928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*